Sign up to get free evidence-based articles, exclusive discounts, and insights from industry-leaders.
Email could not be subscribed.
Thank you for signing up!
presented by Andrew J. Opett, PT, DPT, OCS
Financial— Andrew Opett receives compensation from MedBridge for the production of this course. There are no other relevant financial relationships. Nonfinancial— No relevant nonfinancial relationship exists.
Satisfactory completion requirements: All disciplines must complete learning assessments to be awarded credit, no minimum score required unless otherwise specified within the course.
MedBridge is committed to accessibility for all of our subscribers. If you are in need of a disability-related accommodation, please contact [email protected]. We will process requests for reasonable accommodation and will provide reasonable accommodations where appropriate, in a prompt and efficient manner.
Andrew J. Opett, PT, DPT, OCS
Andrew Opett received a bachelor of science degree in biology from the State University of New York at Geneseo in 1996; a bachelor of science degree in health sciences from Nazareth College of Rochester, New York, in 2000; and a master of science degree in physical therapy from Nazareth College of Rochester, New York, in…
Read full bioEmail could not be subscribed.
Thank you for signing up!
Thank you!
1. Pharmacological Principles
In this chapter, basic pharmacological principles will be discussed as they pertain to rehabilitation professionals. Drug nomenclature, a review of the controlled substances act, and drug safety considerations will also be covered. The importance of performing a medication review during the patient history will be emphasized.
2. Pharmacokinetics
This chapter will discuss the concept of pharmacokinetics. Drug administration, distribution, metabolism, and excretion will be covered as well as the importance of these concepts for the rehabilitation patient.
3. Pharmacodynamics
This chapter will discuss the concept of pharmacodynamics. The biochemical or physiological effects a medication has on the body will be reviewed. The principles of mechanism of action, drug-receptor interactions, and dose response relationships will be covered.
4. Autonomic Pharmacology
This chapter will review the normal functions of the sympathetic and parasympathetic nervous system. The effects of cholinergic and adrenergic agonists and antagonists will be discussed as they pertain to drug actions and side effects.
5. Cardiovascular Drugs
This chapter will explore the effects of drugs used to treat hypertension, cardiac arrhythmias, heart failure, and hyperlipidemia. The effects of these medications on the rehabilitation patient will be emphasized.
6. CNS Drugs
This chapter will discuss the medications used to alter activity within the brain and spinal cord. A review of neurotransmitters will be covered. Specific classes of medications including the sedative and hypnotic drugs, antipsychotic drugs, antiepileptic drugs, drugs for Parkinson’s Disease, and drugs used to treat affective disorders will also be discussed.
7. Pain and Inflammatory Medications
This chapter will review the drugs that are commonly prescribed to treat pain and inflammatory conditions. The opioid analgesics, NSAIDs, and drugs used to manage pain associated rheumatoid arthritis and osteoarthritis will be discussed. Safety concerns with regard to the use of these medications in the rehabilitation patient will be addressed.
8. Drugs Used to Treat Endocrine Disorders and Adrenal System Disorders
This chapter will discuss the drugs commonly used to treat endocrine disorders including diabetes, thyroid disorders, and adrenal system disorders. Safety concerns in the rehabilitation patient will also be covered.
9. Review of Patient Medications by the Rehabilitation Professional
This chapter will discuss the process by which the rehabilitation professional can conduct a review of patient medications. The 2015 Beers criteria published by the American Geriatrics Society for identification of potentially inappropriate medication use in older adults will also be addressed. Identification of credible sources of drug information as well as modes of inquiry when safety issues arise will be included.
10. Q&A
This chapter is a viewer submitted question and answer session, facilitated by Andrew Opett.
Email could not be subscribed.
Thank you for signing up!
Email could not be subscribed.
Thank you for signing up!
For groups of 5 or more, request a demo to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.